GlassScriptPhysician profile
George C Graves
NPI 1043248420
$4,124.34
in general payments reported to CMS, 2019-2025
29 companies · $16.55 in 2025
The $16.55 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $945 · 2021: $911 · 2022: $178 · 2023: $642 · 2024: $346 · 2025: $16.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.62 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $626.11 | 2019-2021 | |
| Lilly USA, LLC | $622.36 | 2019-2024 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $499.26 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $249.72 | 2019-2024 | Nuplazid |
| Amgen INC. | $223.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.82 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $193.55 | 2019-2021 | |
| Ceribell, INC. | $188.34 | 2023 | Ceribell Rapid Response Eeg |
| Pfizer INC. | $181.73 | 2019-2024 | |
| Adamas Pharmaceuticals, INC. | $178.98 | 2019-2021 | |
| Eisai INC. | $122.59 | 2020-2021 | |
| Allergan, INC. | $121.58 | 2020 | |
| Sk Life Science, INC. | $109.86 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $92.88 | 2019-2023 | Rytary |
| Neurelis, INC. | $90.24 | 2023 | Valtoco |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.88 | 2019-2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $57.26 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.55 | 2021 | |
| Avanir Pharmaceuticals, INC. | $49.30 | 2019 | |
| Abbott Laboratories | $34.94 | 2024 | Infinity |
| Arbor Pharmaceuticals, INC. | $30.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $21.77 | 2021 | |
| Tanabe Pharma America, INC. | $20.59 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.80 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.51 | 2021 | |
| Zyla Life Sciences, INC. | $14.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.90 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.